Videos

For early relapsed myeloma, see how patient, disease, and prior therapy guide choices—and why teclistamab plus daratumumab shows standout PFS.

This segment addresses one of the most pressing challenges in advanced SCAC: management after progression on first-line carboplatin, paclitaxel, and retifanlimab.

With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses practice-changing presentations from the 2026 ASCO GU Cancers Symposium.

In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate and poor risk disease based on IMDC criteria and how this influences first-line treatment selection. Dr. McGregor and Dr. Wulff discuss how NCCN recommendations support both IO-IO and IO-TKI combinations in this population, while emphasizing that clinical context often guides the final decision.

Dr. Costa emphasizes that absence of prior BCMA-directed therapy and treatment history represent fundamental elements guiding treatment decisions.

Dr. Luciano Costa from the University of Alabama at Birmingham introduces this Targeted Oncology Case-Based Peer Perspective presentation on bispecific therapy for relapsed/refractory multiple myeloma.

In this introductory segment on advanced renal cell carcinoma, Dr. Wulff frames the challenge of selecting among multiple NCCN category 1 first-line regimens, including IO-IO and IO-TKI combinations. Dr. McGregor and Dr. Geynisman discuss how they approach treatment selection in clinical practice when several evidence-based options exist.

Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: traditional chemotherapy or biomarker-driven therapy.

Benjamin Izar, MD, PhD, discusses unmet needs in melanoma including drug resistance and brain and liver metastases.

Paul G. Richardson, MD, detailed the strategic integration of mezigdomide into several areas including the unmet need of post CAR T-cell therapy.

Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline combinations beyond relapsed settings.

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and spotlighting new targets like HER2 and Claudin 18.2.

Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into clinical trials.

This segment addresses 2 key clinical questions following the adoption of chemo-immunotherapy in advanced SCAC: which patients benefit most and how long treatment should be continued.

AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral options.

Paul G. Richardson, MD, explains the distinct potential roles and combinations including iberdomide and mezigdomide in multiple myeloma treatment.

Dr David Sallman tailors venetoclax dosing based on transplant candidacy, using 21-day induction for transplant-eligible patients followed by rapid tapering upon response.

PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks similar.

A patient's chronological age is no longer a barrier to allogeneic stem cell transplant in MDS/MPN, according to David Sallman, MD. Proceeding directly to transplant in patients with TP53-mutated disease may lead to optimal outcomes.

Explore why community and academic oncologists collaborate, share expertise, and deliver faster, more nuanced care for complex patients.

Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse strategies like BCMA CAR-T and genomic profiling.

Estelamari Rodriguez, MD, delivers her top takeaways from the 2026 IASLC Targeted Therapies in Lung Cancer meeting.

Learn how to spot myeloma progression, distinguish relapse vs refractory disease, and decide when to treat—especially after lenalidomide maintenance and biochemical relapse.

CLL17 finds fixed-duration venetoclax regimens match continuous ibrutinib at 3 years, boosting confidence in personalized frontline CLL choices.

New DLBCL trials test bispecifics with chemo, BTK add-ons, and MRD-guided preemptive allo CAR-T to cut relapse risk.

Erica Pimenta, MD, PhD, discusses her research into using existing GLP-1 receptor agonists in dedifferentiated liposarcoma.

Lymphoma care still leaves gaps—research aims for higher cure rates, longer remission, and fewer toxicities across B-, T-cell and Hodgkin.

ADCs revolutionize breast cancer care, expanding beyond HER2-positive to HER2-low tumors, reshaping early therapy—and spotlighting MRD testing as the next frontier.

Lymphoma care shifts beyond harsh chemo as CAR T, bispecific antibodies, and antibody-drug conjugates deliver stronger, safer treatment.